ImmunoScape Secures G-Rex Grant to Boost TCR-T Therapies
In a significant step forward for immunotherapy, ImmunoScape Pte. Ltd., a leader in TCR-T cell therapy, has been awarded the G-Rex Grant. This initiative, backed by ScaleReady, along with Wilson Wolf Manufacturing and Bio-Techne Corporation (NASDAQ: TECH), offers a generous grant of $250,000. This funding will greatly enhance ImmunoScape's process development and IND enabling studies for their pioneering WT1-targeted TCR-T cell therapy.
The Importance of the G-Rex Grant
This funding is expected to play a crucial role in advancing ImmunoScape's mission to move their groundbreaking therapy closer to clinical use. Dr. Tania Ribeiro, Senior Director and Head of CMC, shared her appreciation for the G-Rex Grant Program, noting its critical impact on reducing the time and costs involved in preparing for clinical trials.
Accelerating Clinical Goals
John Wilson, CEO of Wilson Wolf and co-creator of the G-Rex technology, pointed out that the program aims to fast-track ImmunoScape's ability to provide the robust clinical data that investors are looking for. With the help of G-Rex technology and the support from this grant, ImmunoScape is positioned to make meaningful progress in their TCR-T cell therapy development.
Improving Manufacturing with G-Rex
The G-Rex Grant will allow ImmunoScape to incorporate Wilson Wolf's cutting-edge G-Rex bioreactors into its preclinical development. The innovative ProPak™ GMP Cytokines produced by Bio-Techne, which are specially designed for G-Rex, will facilitate the preparation and administration of essential reagents in a GMP setting. This partnership is expected to cut costs and simplify production, with potential savings reaching thousands of dollars per manufacturing run.
Generating High-Quality IND Data
Additionally, the G-Rex Grant will support the technology transfer of ImmunoScape's distinctive manufacturing process to its Contract Development and Manufacturing Organization (CDMO) partner. This assistance will include training and engineering runs that are vital for creating the necessary manufacturing batch records, a critical requirement for their upcoming IND submission to the FDA.
ScaleReady’s Innovative Role in Gene Therapy
The G-Rex Grant Program initiated by ScaleReady is an impressive $20 million effort designed to support the advancement of cell and gene-modified therapies (CGT). Grants can reach up to $300,000, providing recipients with access to a consortium of partners equipped with state-of-the-art tools, technologies, and substantial expertise in areas such as cGMP manufacturing and regulatory affairs, among others.
Promoting Next-Gen Cancer Treatments
ImmunoScape's dedication to crafting next-generation TCR-T cell therapies places it at the frontline of innovative cancer treatment solutions. Their approach merges Deep Immunomics with AI-driven insights to pinpoint TCRs with the most promising therapeutic potential. As they continue with programs in the discovery phase and gear up for clinical development, ImmunoScape is resolute in its goal to deliver transformative therapies to the market.
Why G-Rex Matters in CGT Development
The G-Rex manufacturing platform is in use by over 800 organizations and is pivotal in about 50% of current CGT clinical trials, also contributing to marketed CGT therapies. ScaleReady's expertise enables CGT companies to save precious time and financial resources, bringing them closer to commercially successful therapies. The collaboration with partners like Bio-Techne and Wilson Wolf further elevates the prospects for groundbreaking advancements in treatment methodologies.
Frequently Asked Questions
What exactly is the G-Rex Grant and who benefits from it?
The G-Rex Grant is a funding initiative by ScaleReady specifically designed to support the development of cell and gene-modified therapies, benefiting organizations such as ImmunoScape.
How will ImmunoScape make use of the grant funds?
The funds will support the development of IND-enabling studies and will improve their manufacturing processes by providing access to advanced bioreactors and cytokines.
What makes G-Rex technology significant?
G-Rex technology offers scalable and efficient manufacturing solutions for cell therapies, which helps reduce costs and enhance production reliability.
What type of therapies is ImmunoScape focused on developing?
ImmunoScape is concentrating on developing TCR-T cell therapies that target solid tumors, employing advanced methods based on Deep Immunomics.
What role does ScaleReady play in the future of CGT?
ScaleReady's resources and strategic partnerships empower organizations involved in gene therapy, helping to accelerate their development processes and fostering innovation in therapeutics.
